Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.
暂无分享,去创建一个
R. Barst | D. Badesch | G. Simonneau | G. Burgess | N. Hill | L. Rubin | N. Galiè
[1] J. Orens,et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. , 2006, Arthritis and rheumatism.
[2] C. Denton,et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era , 2005, Heart.
[3] M. Pillinger,et al. Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension , 2006 .
[4] A. Branzi,et al. Pulmonary arterial hypertension associated to connective tissue diseases , 2005, Lupus.
[5] S. Proudman,et al. Isolated pulmonary hypertension in scleroderma , 2005, Internal medicine journal.
[6] E. Fiumana,et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells , 2005, Basic Research in Cardiology.
[7] M. Ramos-Casals,et al. Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis. , 2004, Rheumatology.
[8] W. Seeger,et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. , 2004, Journal of the American College of Cardiology.
[9] Z. Bshouty. Bosentan in Pulmonary Arterial Hypertension Related to Connective Tissue Disease with Moderate to Severe Pulmonary Fibrosis , 2004 .
[10] R. Barst,et al. Sitaxsentan Improves 6MW in Patients with Pulmonary Arterial Hypertension (PAH) Related to Connective-Tissue Diseases (CTD) , 2004 .
[11] S. Rich,et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. , 2004, Chest.
[12] A. Torbicki,et al. Diagnosis and differential assessment of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.
[13] M. Humbert,et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.
[14] K. Budde,et al. Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[15] B. Raju,et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. , 2004, Journal of the American College of Cardiology.
[16] S. Rosenkranz,et al. Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the raynaud phenomenon. , 2003, Annals of internal medicine.
[17] C. Denton,et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach , 2003, Annals of the rheumatic diseases.
[18] L. Cea-Calvo,et al. Sildenafilo como sustituto de prostaciclina subcutánea en la hipertensión pulmonar , 2003 .
[19] A. Berman,et al. Systemic lupus erythematosus-associated pulmonary hypertension: good outcome following sildenafil therapy , 2003, Lupus.
[20] S. Kimmel,et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. , 2003, Chest.
[21] M. Humbert,et al. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. , 2003, Rheumatology.
[22] P. Escribano Subías,et al. [Sildenafil as a substitute for subcutaneous prostacyclin in pulmonary hypertension]. , 2003, Archivos de bronconeumologia.
[23] D. Badesch,et al. Pulmonary hypertension associated with connective tissue disease. , 2002, Progress in cardiovascular diseases.
[24] Hiroshi Watanabe,et al. Sildenafil for primary and secondary pulmonary hypertension , 2002, Clinical pharmacology and therapeutics.
[25] Avid,et al. BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .
[26] R. Barst,et al. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. , 2000, Chest.
[27] Stuart Rich,et al. Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.
[28] J. Corbin,et al. Cyclic GMP Phosphodiesterase-5: Target of Sildenafil* , 1999, The Journal of Biological Chemistry.
[29] M. Humbert,et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. , 1999, The European respiratory journal.
[30] S. Rich,et al. Compassionate Use of Continuous Prostacyclin in the Management of Secondary Pulmonary Hypertension: A Case Series , 1999, Annals of Internal Medicine.
[31] M Abu-Shakra,et al. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. , 1996, British journal of rheumatology.
[32] T. Medsger,et al. Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3RNP antibody. , 1996, The Journal of rheumatology.
[33] B. Groves,et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.
[34] E H Bergofsky,et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .
[35] T. Medsger,et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. , 1986, Arthritis and rheumatism.